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Abstract
Background
Leishmaniasis is the world’s second deadliest parasitic disease after malaria, and current
treatment of the different forms of this disease is far from satisfactory. Alkylphospholipid
analogs (APLs) are a family of anticancer drugs that show antileishmanial activity, including
the first oral drug (miltefosine) for leishmaniasis and drugs in preclinical/clinical oncology tri-
als, but their precise mechanism of action remains to be elucidated.
Methodology/Principal findings
Here we show that the tumor cell apoptosis-inducer edelfosine was the most effective APL,
as compared to miltefosine, perifosine and erucylphosphocholine, in killing Leishmania spp.
promastigotes and amastigotes as well as tumor cells, as assessed by DNA breakdown
determined by flow cytometry. In studies using animal models, we found that orally-adminis-
tered edelfosine showed a potent in vivo antileishmanial activity and diminished macrophage
pro-inflammatory responses. Edelfosine was also able to kill Leishmania axenic amastigotes.
Edelfosine was taken up by host macrophages and killed intracellular Leishmania amasti-
gotes in infected macrophages. Edelfosine accumulated in tumor cell mitochondria and
Leishmania kinetoplast-mitochondrion, and led to mitochondrial transmembrane potential
disruption, and to the successive breakdown of parasite mitochondrial and nuclear DNA.
Ectopic expression of Bcl-XL inhibited edelfosine-induced cell death in both Leishmania
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parasites and tumor cells. We found that the cytotoxic activity of edelfosine against Leish-
mania parasites and tumor cells was associated with a dramatic recruitment of FOF1-ATP
synthase into lipid rafts following edelfosine treatment in both parasites and cancer cells. Raft
disruption and specific FOF1-ATP synthase inhibition hindered edelfosine-induced cell death
in both Leishmania parasites and tumor cells. Genetic deletion of FOF1-ATP synthase led to
edelfosine drug resistance in Saccharomyces cerevisiae yeast.
Conclusions/Significance
The present study shows that the antileishmanial and anticancer actions of edelfosine share
some common signaling processes, with mitochondria and raft-located FOF1-ATP synthase
being critical in the killing process, thus identifying novel druggable targets for the treatment
of leishmaniasis.
Author summary
Leishmaniasis is a major health problem worldwide, and can result in loss of human life or a
lifelong stigma because of bodily scars. According to World Health Organization, leishmani-
asis is considered as an emerging and uncontrolled disease, and its current treatment is far
from ideal, with only a few drugs available that could lead to drug resistance or cause serious
side-effects. Here, we have found that mitochondria and raft-located FOF1-ATPase synthase
are efficient druggable targets, through which an ether lipid named edelfosine exerts its antil-
eishmanial action. Edelfosine effectively kills Leishmania spp. promastigotes and amastigotes.
Our experimental animal models demonstrate that oral administration of edelfosine exerts a
potent antileishmanial activity, while inhibits macrophage pro-inflammatory responses. Our
results show that both Leishmania and tumor cells share mitochondria and raft-located
FOF1-ATPase synthase as major druggable targets in leishmaniasis and cancer therapy. These
data, showing a potent antileishmanial activity of edelfosine and unveiling its mechanism of
action, together with the inhibition of the inflammatory responses elicited by macrophages,
suggest that the ether lipid edelfosine is a promising oral drug for leishmaniasis, and highlight
mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets for the
treatment of this disease.
Introduction
Leishmaniasis, caused by several species of the protozoan Leishmania parasite, is one of the
world’s most neglected diseases in terms of drug research and development, and for which cur-
rent therapy is not satisfactory [1]. At present, about 350 million people in 98 countries world-
wide are at risk of contracting leishmaniasis, and some 0.9–1.6 million new cases occur yearly,
with about 0.7–1.2 million cases of self-healing cutaneous leishmaniasis, which can result in dis-
figuring skin lesions, and 0.2–0.4 million cases per year of life-threatening visceral leishmaniasis,
which is a fatal disease if left untreated [1–3]. Leishmaniasis is the world’s second-deadliest par-
asitic disease after malaria, with a tentative estimate of 20,000 to 40,000 leishmaniasis deaths
occurring annually [3], and has been classed as a category 1 disease (“emerging and uncon-
trolled”) by the World Health Organization (WHO). At present there are very few available
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antileishmanial drugs, being in general toxic, and the first line drugs are becoming ineffective
due to emerging drug resistance [1, 2]. Thus, the development of novel therapeutic drugs is
urgently needed. Leishmaniasis is transmitted by the bite of a female sandfly vector (Lutzomyia
in the Americas and Phlebotomus elsewhere) infected with Leishmania parasites. Infection of
humans and other animal hosts is initiated by flagellated promastigotes that develop within the
digestive tract of the sandfly vector and are injected during a sandfly blood meal. Promastigotes
are internalized into a number of phagocytic host cells, including neutrophils, dendritic cells,
and macrophages, but proliferate only within the macrophage as aflagellate amastigotes [4, 5].
The so-called alkylphospholipid analogs (APLs) constitute a class of structurally-related
antitumor compounds with multiple therapeutic indications, and include a number of clini-
cally relevant and/or promising drugs, such as miltefosine (hexadecylphosphocholine), edelfo-
sine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine), perifosine (octadecyl
(1,1-dimethyl-piperidinio-4-yl)-phosphate) and erucylphosphocholine ((13Z)-docos-13-en-
1-yl 2-(trimethylammonio)ethyl phosphate) (ErPC) (Fig 1) [6–8]. So far, miltefosine is the
only APL that has entered the clinic, registered as Impavido, the first orally-effective treatment
for visceral leishmaniasis, and as Miltex, a topical chemotherapy and palliative treatment in
cutaneous metastases from breast cancer [7, 9, 10]. APLs induce an apoptosis-like cell death in
Leishmania parasites [11, 12], but their antiparasitic mechanism of action remains unknown,
although lipid metabolism [13] and dramatic increases in membrane dynamics [14] have been
suggested to play a role.
The ether lipid edelfosine induces apoptosis in tumor cells, involving cholesterol-rich lipid
rafts and mitochondria [15–20]. Lipid rafts are membrane microdomains highly enriched in
cholesterol and sphingolipids, and recent findings in mammalian cells suggest that lipid rafts
act as death-promoting scaffolds, where Fas/CD95 and downstream signaling molecules are
recruited to tigger apoptosis [21–23]. Raft domains have also been described in Leishmania
spp., although their biochemical and functional characterization remains incomplete [24].
Fig 1. Chemical structures of APLs and edelfosine fluorescent analog PTE-ET used in this
manuscript. The chemical structure of phosphatidylcholine (PC) is also shown. Me, methyl group.
https://doi.org/10.1371/journal.pntd.0005805.g001
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Here, we analyzed whether our knowledge on processes involved in the anticancer activity
of APLs could provide some insight into their antileishmanial mechanism of action. In addi-
tion, we tested the effect of APLs on intact and Leishmania-infected macrophages as the main
host cells for Leishmania parasites, as well as the in vivo antileishmanial activity of edelfosine
in animal models. In this study, we report the existence of common mechanisms that underlie
the antileishmanial and antitumor activities of the APL edelfosine, involving mitochondria,
lipid rafts and FOF1-ATP synthase (also named as FOF1-ATPase), which might open up new
avenues for the development of novel targeted therapies.
Materials and methods
Ethics statement
Animal procedures were approved by the institutional research commission of the University
of Salamanca, and were approved by the Ethics Committee of the University of Salamanca
(protocol approval number 48531). Animal procedures complied with the Spanish (Real
Decreto RD1201/05) and the European Union (European Directive 2010/63/EU) guidelines
on animal experimentation for the protection and humane use of laboratory animals, and
were conducted at the accredited Animal Experimentation Facility (Servicio de Experimenta-
cio´n Animal) of the University of Salamanca (Register number: PAE/SA/001).
Drugs and reagents
Edelfosine was from R. Berchtold (Biochemisches Labor, Bern, Switzerland). Miltefosine was
from Calbiochem (Cambridge, MA). Perifosine and erucylphosphocholine were from Zentaris
(Frankfurt, Germany). Rotenone, malonate, antimycin A, azide, oligomycin and CCCP were
from Sigma (St. Louis, MO).
Cells and culture conditions
The Leishmania strains used in this study were: L. donovani (MHOM/IN/80/DD8), L. major
LV39 (MRHO/SU/59/P), L. panamensis (MHOM/CO/87/UA140), L. infantum (MCAN/ES/96/
BCN/150, MON-1), kindly provided by Iva´n D. Ve´lez (Programa de Estudio y Control de Enfer-
medades Tropicales–PECET-, Medellin, Colombia), Ingrid Mu¨ller (Imperial College London,
London, UK) and Antonio Jime´nez-Ruiz (Universidad de Alcala´, Alcala´ de Henares, Spain). To
visualize Leishmania parasites inside macrophages we used GFP-L. panamensis promastigotes
[25, 26]. Leishmania promastigotes were grown at 26˚C in RPMI-1640 culture medium (Invitro-
gen, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100
U/ml penicillin, and 100 μg/ml streptomycin. Promastigotes were treated at 26˚C with the indi-
cated compounds during their logarithmic growth phase (1.5 x 106 parasites/ml). Late stationary
promastigotes were obtained after incubation of the parasites for more than 6 days with a start-
ing inoculum of 1 x 106 parasites/ml. Leishmania axenic amastigotes were obtained as previously
described [27]. Human acute T-cell leukemia Jurkat (American Type Culture Collection, Manas-
sas, VA), myeloid leukemia HL-60 (American Type Culture Collection), multiple myeloma
MM144 (provided by A. Pandiella, CIC, IBMCC, Salamanca, Spain), and cervical carcinoma
HeLa (American Type Culture Collection) cell lines, as well as the mouse macrophage cell line
J774 (American Type Culture Collection) were grown in RPMI-1640 culture medium supple-
mented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin at
37˚C in humidified 95% air and 5% CO2.
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Yeast experiments and growth conditions
Saccharomyces cerevisiae yeast (BY4741 strain: MATa his3Δ1 leu2Δ0met15Δ0 ura3Δ0) was
grown on standard synthetic complete medium (SDC), which consisted of synthetic minimal
medium (SD; 0.17% yeast nitrogen base without amino acids, 2% glucose and supplements
according to the requirements of the strains) with 0.079% complete supplement mixture (For-
Medium, Norwich, UK). Yeast cultures were incubated at 30˚C, and growth of cells untreated
or treated with edelfosine was monitored by optical density at a wavelength of 595 nm (OD595).
Cells were incubated for the indicated times and sample aliquots were taken to measure absor-
bance at 595 nm. Edelfosine was used at the concentrations indicated in the corresponding fig-
ure in liquid medium. The atp7Δ mutant was obtained from the EUROSCARF haploid deletion
library in the BY4741 background [28]. This atp7Δ mutant was complemented with the corre-
sponding wild-type gene expressed from a centromeric plasmid (pRS416), and yeast growth
was determined as above.
Bcl-XL transfection
L. infantum transfected with pX63-Neo or pX63-bcl-xL were kindly provided by Antonio Jime´-
nez-Ruiz (Universidad de Alcala´, Alcala´ de Henares, Spain) and grown in medium containing
100 μg/ml G418 (Sigma) [29]. HeLa cells (1–2 x 105) were transfected with 2 μg of pSFFV-bcl-
xL or pSFFV-Neo expression vector [15], using Lipofectin reagent (Life Technologies, Carls-
bad, CA). Transfected clones were selected by growth in the presence of 500 μg/ml G418, and
monitored by Western blotting using the 2H12 anti-29 kDa Bcl-XL monoclonal antibody (BD
Biosciences PharMingen, San Diego, CA).
Generation of mouse bone marrow-derived macrophages (BMM)
Murine bone marrow cells were obtained by flushing out the femurs of mice from (C57BL/6 x
BALB/c)F1 (CBF1) mice and cultured as previously described [30] in hydrophobic Teflon bags
(Biofolie 25, Heraeus, Hanau, Germany) with DMEM culture medium containing 10% FBS,
5% horse serum, 2 mM L-glutamine, 60 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 1%
non-essential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin, and the supernatant
of L929 fibroblasts at a final concentration of 15% (v/v) as a source of colony-stimulating fac-
tors which drive cells towards a>95% pure BMM [31].
BMM obtained from edelfosine-treated mice
CBF1 mice were treated orally with edelfosine (5 mg/kg body weight), daily for 13 days in 100
μl PBS, and then BMM were prepared as above. No weight loss or other visible side-effects
were observed in mice treated with edelfosine.
Macrophage cell viability assay
Cell viability at the indicated times was measured by the WST-1 reduction to formazan
method (Roche Diagnostics, Basel, Switzerland). 105 cells were incubated for 2 h at 37˚C with
10 μl WST-1 solution in 0.2 ml DMEM culture medium supplemented with 10% FBS in a flat-
bottom microtitre plate, and then absorbance was determined at 440 nm.
Determination of superoxide anion
The production of superoxide anion (2 x 105 cells in 0.2 ml Hepes-DMEM without pH indica-
tor and containing 125 μM lucigenin, 37˚C) was initiated by addition of 50 μg zymosan, and
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measured as lucigenin-dependent chemiluminescence using a Microlumat LB96P (Berthold,
Wildbad, Germany) [32].
Nitric oxide (NO) determination
NO end product nitrite was measured using the Griess reagent as previously described [32].
Culture supernatant was mixed with 100 μl of 1% sulphanilamide, 0.1% N-(1-naphthyl)ethyle-
nediamine dihydrochloride and 2.5% H3PO4. Absorbance was measured at 540 nm in a micro-
plate reader (Molecular Devices, Ismaning, Germany). LPS from S. abortus equi was kindly
provided by Chris Galanos (Max-Planck-Institut, Freiburg, Germany).
IFN-γ assay
IFN-γ was determined by a commercially available (Pharmingen) sandwich ELISA test accord-
ing to the manufacturer’s protocol.
Determination of intracellular ATP level
The ATP content was determined by the luciferin–luciferase method [33]. The assay is based
on the requirement of luciferase for ATP in producing light (emission maximum 560 nm at
pH 7.8). Briefly, cells (2 x 106) were harvested after treatment, resuspended in 1X PBS, and
assayed for ATP using the Molecular Probes ATP determination kit (Thermo Fisher Scientific,
Waltham, MA). The amount of ATP in each experimental sample was calculated from a stan-
dard curve prepared with ATP and expressed as percentage of the amount of ATP found in
untreated control cells.
Analysis of apoptosis-like cell death by flow cytometry
1.5 x 106 Leishmania spp. promastigotes or axenic amastigotes, and 106 Jurkat cells or other
human cells were incubated in the absence or presence of the indicated concentrations of
APLs for different incubation times, and then analyzed for DNA breakdown by flow cytome-
try, using a fluorescence-activated cell sorting (FACS)Calibur flow cytometer (Becton Dickin-
son, San Jose, CA), as previously described [16]. Quantitation of apoptotic-like cells was
monitored following cell cycle analysis as the percentage of cells in the sub-G0/G1 region, rep-
resenting hypodiploids or apoptotic-like cells [16].
Cytofluorimetric analysis of mitochondrial transmembrane potential
(ΔΨm) and generation of reactive of oxygen species (ROS)
2 x 106 Leishmania parasites and 106 Jurkat cells were pelleted by centrifugation, washed with
PBS, incubated in 1 ml PBS containing 20 nM 3,30-dihexyloxacarbocyanine-iodide (DiOC6(3),
green fluorescence; Molecular Probes, Leiden, The Netherlands) and 2 μM dihydroethidine (HE,
red fluorescence after oxidation; Sigma) at room temperature and darkness for 20 min, and then
analyzed on a Becton Dickinson FACSCalibur flow cytometer as previously described [16].
Macrophage infection
Macrophages, cultured in RPMI 1640 culture medium containing 10% FBS, were incubated
for 4 h with stationary-phase L. panamensis promastigotes at a 10:1 parasite-to-macrophage
ratio. Then, cell monolayers were extensively washed and incubated in complete culture
medium with or without edelfosine for 24 h. The intracellular parasite load was calculated by
limiting dilution assay as previously reported [34]. Alternatively, macrophage monolayers
infected with green fluorescent protein (GFP)-expressing p6.5-egfp-L. panamensis parasites
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were cultured in glass coverslips placed into culture vessels (Corning, Lowell, MA). After 24 h,
coverslips were washed, and the rate of intracellular amastigotes and infected macrophages
was visualized using a fluorescence microscope. Results are shown as the percentage of
infected macrophages and as the parasite/macrophage ratio after counting 100 macrophages.
In vivo antileishmanial activity
Four-week-old male Syrian golden hamsters (Mesocricetus auratus) (about 120 g) were
obtained from Charles River Laboratories (Lyon, France) and maintained in a pathogen-free
facility. Animals were handled according to institutional guidelines, complying with the Span-
ish legislation, in an animal room with 12-h light/dark cycle at a temperature of 22˚C, and
received a standard diet and water ad libitum. Hamsters were inoculated intradermally in the
nose with 1 x 106 stationary-phase promastigotes in a volume of 50 μl PBS and treated with a
daily oral administration of edelfosine (20 mg/kg in water), or an equal volume of vehicle
(water) as previously described [26]. Nose swelling was evaluated through weekly caliper mea-
surements, and compared with the nose size before inoculation and treatment. Evolution
index of the lesion was calculated as the size (mm) of the lesion during treatment/size of the
lesion before treatment. No loss in animal body weight and no sign of morbidity were detected
during the 28-day drug treatment, and animals were killed, following institutional guidelines,
24 h after the last drug administration. Parasite burden in the infected tissues was calculated by
limiting dilution assay as previously described [26].
TUNEL assay
Apoptosis-like cell death was also analyzed in situ by the TUNEL technique using the Fluores-
cein Apoptosis Detection System (Promega, Madison, WI), according to the manufacturer’s
instructions. Parasites were fixed with 4% formaldehyde for 20 min on microscope slides, per-
meabilized with 0.2% Triton X-100, stained for fragmented DNA using the above kit, and then
propidium iodide was added for 15 min to stain both apoptotic-like and intact cells as previ-
ously described [17, 35, 36]. Propidium iodide stained all cells in red, whereas fluoresecin-
12-dUTP was incorporated at the 3’-OH ends of fragmented DNA, resulting in localized green
fluorescence within the nucleus of apoptotic-like cells. Samples were analyzed with a Zeiss
LSM 510 laser scan confocal microscope (Carl Zeiss AG, Jena, Germany).
Edelfosine localization by fluorescence microscopy
L. panamensis and HeLa cells were treated for 1 h with 10 μM fluorescent edelfosine analog all-
(E)-1-O-(15’-phenylpentadeca-8’,10’,12’,14’-tetraenyl)-2-O-methyl-rac-glycero-3-phosphocho-
line (PTE-ET) (Fig 1), kindly provided by F. Amat-Guerri and A.U. Acuña (Consejo Superior
de Investigaciones Cientificas, Madrid, Spain) as described [17, 36, 37], and then incubated
with 100 nM cell-permeant MitoTracker probe (Molecular Probes) for 20 min to label mito-
chondria. Colocalization was analyzed by excitation of the corresponding fluorochromes in the
same section of samples, using a fluorescence microscope (Axioplan 2; Carl Zeiss MicroIma-
ging, Inc., Oberkochen, Germany) and a digital camera (ORCA-ER-1394; Hamamatsu, Hama-
matsu City, Japan).
Disruption of lipid microdomains in Leishmania promastigotes and Jurkat
cells
Parasites (2 x 106/ml) were incubated in serum-free medium with 2.5 mg/ml methyl-β-cyclo-
dextrin (MCD) for 40 min at 26˚C, and then washed 3 times with PBS, and resuspended in
Mitochondria and raft-located FOF1-ATPase in
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005805 August 22, 2017 7 / 31
complete culture before edelfosine addition. For cholesterol depletion in Jurkat cells, 2.5 x 105
cells/ml were incubated with 2.5 mg/ml MCD for 30 min at 37˚C in serum-free medium, and
then washed 3 times with PBS, and resuspended in complete culture before edelfosine
addition.
Edelfosine uptake
Drug uptake was measured as previously described [15, 36], after incubating 2 x 106 parasites
or 106 Jurkat cells with 10 nmol [3H]edelfosine (10 μM) (Amersham Buchler, Braunschweig,
Germany) for 1 h in RPMI-1640, 10% FBS, and subsequent washing (six times) with PBS + 2%
BSA. [3H]edelfosine (specific activity, 42 Ci/mmol) was synthesized by tritiation of the 9-octa-
decenyl derivative (Amersham Buchler, Braunschweig, Germany).
Lipid raft isolation
Lipid rafts were isolated from 1 x 108 Leishmania promastigotes or 8×107 Jurkat cells by using
nonionic detergent lysis conditions and centrifugation on discontinuous sucrose gradients as
previously reported [38, 39]. Twelve 1-ml fractions were collected from the top of the gradient,
and 25 μl of each fraction were subjected to sodium dodecylsulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) and assayed for the location of GM1-containing lipid rafts using the
GM1-specific ligand cholera toxin (CTx) B subunit conjugated to horseradish peroxidase
(Sigma, St. Louis, MO).
Two-dimensional gel electrophoresis
The proteomic analysis was performed in the proteomics facility of Centro de Investigacio´n
del Ca´ncer (CIC), Salamanca, Spain, which belongs to ProteoRed, PRB2-ISCIII. Samples
(100 μg protein) from pooled fractions enriched in lipid rafts (fractions 3–6 from the sucrose
gradient) were precipitated with methanol/chloroform, and then the pellets were resuspended
in rehydration buffer (7 M urea, 2M thiourea, 4% CHAPS, 50 mM DTT, 5 mM TCEP, 15 mg
DeStreak, 0.5% IPG buffer). Samples were applied to 13 cm IPG strips with a nonlinear pH
gradient of 3 to 10 (Amersham Biosciences). Isoelectric focusing was performed at 50 V for 12
hours, 500 V for 1 h, 1000 V for 1 h, a voltage gradient ranging from 1000 to 8000 V for 30
min, and finally 5 h until the voltage reached 35000 V. Strips were treated with SDS equilibra-
tion buffer (375 mM Tris-HCl pH 8.8, 6 M urea, 20% glycerol, 2% SDS) plus 2% DTT for 15
min for protein denaturation, and then with equilibration buffer plus 2.5% iodoacetamide for
protein alkylation. The second dimension electrophoresis was performed on 10% SDS-poly-
acrylamide gels. The protein spots were visualized with Sypro Ruby Protein Gel Staining (Invi-
trogen, Carlsbad, CA).
Spot excision, tryptic digestion of proteins, mass determination and
protein identification
Spots of interest were automatically excised with Proteineer Spot Picker robotics workstation
(Bruker Daltonics, Billerica, MA). The digestion was performed as previously described [40].
For MALDI-TOF peptide mass fingerprinting, a 0.5 μl aliquot of matrix solution (5 g/l
2,5-dihydroxybenzoic acid in 33% aqueous acetonitrile plus 0.1% trifluoroacetic acid) was
manually loaded onto a 400 μm diameter AnchorChip Target plate (Bruker Analytic GmbH,
Bremen, Germany) probe, and 1 μl of the above peptide extraction solution was added and
allowed to dry at room temperature. Samples were analyzed on a Bruker Ultraflex MALDI-
TOF mass spectrometer (Bruker-Franzen Analytic GmbH, Bremen, Germany). Each raw
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spectrum was opened in FlexAnalysis 3.0 (Bruker Daltonics) software and processed and ana-
lyzed using the following parameters: signal-to-noise threshold of 1, Savitzky-Golay algorithm
for smoothing, tangential algorithm for baseline substraction, and centroid algorithm for
monoisotopic peak assignment. In all cases, resolution was higher than 9000. The generated
peaks were submitted to Mascot Server (version 2.2, February 2007) [41] using Bio Tools 3.1
(Bruker Daltonics) software, and searched against Uniprot database for human sequences and
NCBI database for Leishmania sequences. Search parameters were set as follow: searches were
restricted to all sequences for human searches and Other Eukaryota (69482 sequences) for
Leishmania searches, up to one missed tryptic cleavage, mass accuracy of 100 ppm, MH+
monoisotopic masses, carbamidomethyl cysteine as fixed modification, and methionine oxida-
tion as variable modification. Mowse scores with a value greater than 65 for human searches
and 61 for Leishmania searches were considered as significant (p<0.05).
Statistical analysis
Data are shown as mean ± SD. Between-group statistical differences were assessed using the
Student’s t test. A P-value of<0.05 was considered statistically significant.
Results
Differential capacity of APLs in promoting cell death in Leishmania spp.
and human cancer cells with apoptosis-like characteristics
First we analyzed the ability of different APLs (Fig 2A and 2B) in promoting apoptosis-like cell
death in different Leishmania spp. promastigotes and human cancer cell lines, as assessed by DNA
breakdown determined by flow cytometry. Our results showed that APLs ranked edelfosine>
miltefosine perifosine> erucylphosphocholine (ErPC) for their leishmanicidal activity (Fig 2A),
and edelfosine> perifosine> miltefosineffi erucylphosphocholine (ErPC) for their antitumor
activity (Fig 2B), when incubated for 24 h at 10 μM with several Leishmania spp. promastigotes,
including L. donovani (visceral leishmaniasis), L. panamensis (cutaneous and mucocutaneous leish-
maniasis), and L. major (cutaneous leishmaniasis), or with human cancer cell lines, including mye-
loid leukemia HL-60 cells, multiple myeloma MM144 cells, and cervical cancer HeLa cells. This
drug concentration (10 μM) corresponded to the pharmacologically relevant concentration range
of edelfosine in plasma (10–20 μM), previously determined in a number of in vivo and pharmacoki-
netic studies [19, 42, 43]. We also found that edelfosine was very efficient in promoting cell death
in additional human leukemic cell lines, including human T-cell acute lymphoblastic leukemia
(T-ALL) cell lines Jurkat (53.4 ± 6.2% apoptosis) and CEM-C7H2 (58.2 ± 5.9% apoptosis). Edelfo-
sine was equally effective against different Leishmania subgenera, including Leishmania Leishmania
(L. donovani, L. major) and Leishmania Viannia (L. panamensis) (Fig 2A). The relative difference
between the abilities to promote cell death of edelfosine vs. miltefosine was more evident using
tumor cells than Leishmania spp. promastigotes, suggesting that processes involved in the mecha-
nisms of action of both drugs are partially conserved, but not identical. For the ensuing studies, we
focused our attention on the most effective compound, namely edelfosine, which has been consid-
ered as the APL prototype. Edelfosine induced DNA breakdown after 9-h incubation with L. pana-
mensis promastigotes, and the percentage of parasites with a hypodiploid DNA content (sub-G0/G1
cell population) increased with the incubation time (Fig 2C), suggesting an apoptosis-like cell death
in Leishmania parasites, similar to the apoptotic response triggered in cancer cells [15, 17, 35, 44].
Edelfosine (5 or 10 μM) also induced apoptosis-like cell death, as assessed by an increase in the sub-
G0/G1 population, in L. panamensis axenic amastigotes (Fig 2D).
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Edelfosine accumulates into and kills Leishmania amastigotes in
infected macrophages
Because Leishmania are obligate intracellular parasites that infect macrophages within the
mammalian host, we examined the location of edelfosine in L. panamensis-infected J774 mac-
rophage-like cells. We have previously found that mouse J774 macrophages were rather
Fig 2. In vitro and in vivo antileishmanial activity of the antitumor ether phospholipid edelfosine. Apoptosis-like cell death was quantitated by flow
cytometry as percentage of hypodiploid cells (sub-G0/G1) in different Leishmania spp. promastigotes (A) and human cancer cell lines (myeloid leukemia HL-
60, multiple myeloma MM144, and cervical carcinoma HeLa) (B), following 24-h incubation with distinct APLs (10 μM). Untreated control cells were run in
parallel. ErPC, erucylphosphocholine. (C) Time-course of 10 μM edelfosine-induced apoptosis-like cell death (% hypodiploid cells) in L. panamensis
promastigotes. Untreated control parasites were run in parallel. (D) Induction of apoptosis-like cell death in L. panamensis axenic amastigotes treated with
the indicated concentrations of edelfosine for 16 h. (E) GFP-L. panamensis (GFP-Lp)-infected J774 macrophages were incubated for 1 h with 10 μM PTE-ET
and analyzed by fluorescence microscopy. Incubation of GFP-Lp-infected J774 macrophages with 10 μM edelfosine for 24 h decreased parasite infection (F)
and the number of parasites per macrophage (G), as compared to untreated infected cells (Control). (H) Murine BMM were infected with L. panamensis and
subsequently treated with distinct APLs (10 μM) or vehicle (Control). Parasite load was measured after 3-day incubation. (I-K) Hamsters were inoculated in
the nose with L. panamensis promastigotes, and then treated orally with edelfosine (20 mg/kg, n = 8) or with water vehicle (Control) for 28 days. Evolution
index during treatment (I) and parasite load in the nose at the end of the 4-week treatment (J) were determined. Edelfosine treatment dramatically reduced
nose inflammation and damage at the end of treatment (K). Data shown are means ± SD or representative of three independent experiments performed.
Asterisks indicate that the differences between control and edelfosine-treated groups are statistically significant. (*) P<0.05. (**) P<0.01.
https://doi.org/10.1371/journal.pntd.0005805.g002
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resistant to edelfosine [26], and 10 μM edelfosine was unable to mount an apoptotic response
after 24-h incubation (<2.5% apoptosis). Using the blue-emitting fluorescent edelfosine analog
PTE-ET (Fig 1), a bona fide compound to explore the subcellular localization of edelfosine [17,
19, 36, 37, 45], we found that it was mainly located into the parasites inside the macrophage
(Fig 2E), which were visualized by using infective GFP-L. panamensis parasites [25]. Edelfosine
treatment highly diminished the amount of infected J774 macrophages and the number of par-
asites per macrophage (Fig 2F and 2G). Following limiting dilution experiments, we found
that edelfosine was the most effective APL, when compared to miltefosine, perifosine and eru-
cylphosphocholine (ErPC), in killing L. major amastigotes in infected mouse BMM (Fig 2H).
Edelfosine was highly dependent on its molecular structure for its antileishmanial activity,
since a structurally related compound, ET-18-OH (1-O-octadecyl-rac-glycero-3-phosphocho-
line) (Fig 1), containing a hydroxyl group instead of the methoxy group at the C2 position, was
unable to kill Leishmania protozoa (Fig 2H), similarly to what has been found in cancer cells
[15, 44].
In vivo antileishmanial activity of edelfosine
We have previously shown the potent antitumor activity of orally-administered edelfosine
in different xenograft animal models [19, 43, 46]. Recently, we have also found that edelfo-
sine was effective in the treatment of leishmaniasis in different animal models when used at
26 mg/kg body weight [26]. Here, we found that oral treatment of edelfosine at a lower dose
(20 mg/kg body weight) exerted a potent in vivo antileishmanial activity in L. panamensis–
infected golden hamsters (Fig 2I–2K), an appropriate animal model for reproducing the
pathological features of human leishmaniasis [47]. L. panamensis promastigotes were inocu-
lated into the nose of 16 golden hamsters, and then animals were randomly distributed into
two cohorts of eight hamsters. Each cohort received a daily oral administration of edelfosine
or water vehicle (control) for 28 days. Disease progression was monitored by nasal swelling,
determined by serial caliper measurements, and ulceration. Oral treatment with edelfosine
led to a dramatic decrease in nasal swelling and parasite load at the site of infection (Fig 2I–
2K), and ameliorated the signs of leishmaniasis, leading to an almost normal morphologic
appearance (Fig 2K).
Edelfosine is taken up by macrophages and inhibits the generation of
macrophage-derived pro-inflammatory mediators
Edelfosine has been shown to be taken up preferentially by tumor cells, whereas normal non-
malignant cells incorporated a relatively much lesser amount of the ether lipid [15, 17, 35].
Here, we found that normal mouse BMM took up large amounts of edelfosine, at even higher
levels than the mouse RAW 309 Cr.1 tumor macrophage cell line (Fig 3A). However, edelfo-
sine induced cell death in the transformed macrophage cell line, but spared BMM (Fig 3B).
Interestingly, edelfosine blocked zymosan-induced respiratory burst in BMM (Fig 3C). Fur-
thermore, BMM from mice that were orally treated with edelfosine (5 mg/kg body weight,
daily) for two weeks showed a lower capacity to generate superoxide anion, NO and IL-12+IL-
18-induced IFN-γ, when compared to BMM from mice treated with water vehicle (Fig 3D–
3F). These results suggest that edelfosine treatment decreases macrophage pro-inflammatory
responses. Our data, together with the above accumulation of edelfosine into the parasites in
Leishmania-infected macrophages, suggest that edelfosine-induced killing of Leishmania is
mediated by a direct action of the drug on the parasite, and not via generation of macrophage-
derived antiparasitic molecules.
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Edelfosine induces kinetoplast DNA cleavage prior to nuclear DNA
breakdown
DNA breakdown induced by edelfosine treatment in Leishmania was further assessed by the
TUNEL assay, staining all cells in red through the binding of propidium iodide to DNA, and
only those cells with fragmented DNA and free 3’-OH ends in green. Interestingly, we detected
first kinetoplast-mitochondrial DNA degradation, followed by nuclear DNA fragmentation
upon treatment of L. panamensis promastigotes with edelfosine (Fig 4A). These results suggest
that the death process induced by edelfosine in Leishmania spp. parasites starts at the mito-
chondrial level.
Edelfosine accumulates in the mitochondria of Leishmania and cancer
cells
Next, we analyzed the subcellular localization of edelfosine in Leishmania promastigotes. The
fluorescent edelfosine analog PTE-ET, which has been previously shown to fully mimic the
Fig 3. Edelfosine is taken up by macrophages and inhibits macrophage-derived inflammatory
mediators. (A) Incorporation of edelfosine (EDLF) in mouse bone marrow-derived macrophages (BMM) and
mouse RAW 309 Cr.1 tumor macrophage cell line. 106 cells were incubated with 10 μM edelfosine (containing
0.05 μCi [3H]edelfosine) for the indicated times to measure drug uptake. (B) Edelfosine is cytotoxic for
transformed macrophages but spares BMM. 2 x 106 cells were incubated for 24 h in the absence or presence
of the indicated concentrations of edelfosine (EDLF), and cytotoxicity was determined by the WST-1 reduction
method. (C) Edelfosine inhibits superoxide anion generation in BMM. Superoxide anion was measured as
lucigenin-dependent chemiluminescence (relative light units, RLU) in untreated control (C) or edelfosine
(EDLF)-treated BMM that were incubated with medium alone or zymosan to induce the respiratory burst.
(D-F) BMM from edelfosine-fed mice show a decreased generation of inflammatory mediators. BMM from
untreated control mice (C) and from mice given orally edelfosine (EDLF) for two weeks were analyzed for their
capacity to generate zymosan-induced superoxide anion (D), LPS-induced nitric oxide (E), and IL-12+IL-
18-induced IFN-γ (F). Cells incubated with medium alone were run in parallel as a negative control of each
assay. Data shown are means ± SD of five independent determinations. Asterisks indicate values that are
significantly different from those of control mice (comparison between the black histograms of control and
edelfosine-treated groups) at P<0.05 (*) and P<0.01 (**).
https://doi.org/10.1371/journal.pntd.0005805.g003
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Fig 4. Edelfosine induces breakage of kinetoplast DNA prior to nuclear DNA breakdown, and accumulates in mitochondria in Leishmania
parasites and cancer cells. (A) L. panamensis promastigotes were untreated (Control) or treated with 10 μM edelfosine (EDLF) for 6 and 9 h, and then
analyzed by confocal microscopy for propidium iodide (PI) staining and TUNEL assay. The positions of the nucleus (N) and kinetoplast (K) are indicated by
arrows. Merging of PI and TUNEL panels (Merge) shows the DNA-containing organelles with DNA disruption in yellow. The corresponding differential
interference contrast (DIC) images were included in the Merge panels to highlight parasite morphology and facilitate kinetoplast identification. (B) L.
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antitumor [17, 19, 36, 37, 45, 48] and antileishmanial [49] actions of the parent drug edelfo-
sine, accumulated mainly in the mitochondria of L. panamensis promastigotes, as indicated by
colocalization with the specific mitochondrial marker MitoTracker (Fig 4B). PTE-ET also co-
localized with MitoTracker-positive structures in human cervical carcinoma HeLa cells (Fig
4C).
Mitochondrial involvement in edelfosine-induced Leishmania death
We next examined the time-course of the effect of edelfosine on the following mitochondrial-
related processes in L. panamensis promastigotes: a) ROS generation, through the conversion
of non-fluorescent dihydroethidine (HE) into red fluorescent ethidium (Eth) after its oxida-
tion via ROS; and b) changes in ΔΨm, through the accumulation of the fluorescent cationic
probe DiOC6(3) (green fluorescence), which depends on the mitochondrial potential. As
shown in Fig 5A, untreated parasites exhibited a high ΔΨm [(DiOC6(3))
high], and the levels of
intracellular ROS were undetectable [(HE! Eth)low]. Edelfosine induced first an increase in
the percentage of cells with (HE! Eth)high, and then a loss in ΔΨm (Fig 5A). Changes in ROS
generation and ΔΨm disruption apparently preceded DNA breakdown. Edelfosine induced
Eth staining, i.e. ROS generation, in kinetoplasts, as assessed by using DNA staining to identify
L. panamensis nuclei and kinetoplasts (mitochondrial DNA) (Fig 5B). The inhibitor of the
mitochondrial permeability transition pore cyclosporin A [50], and the antioxidant agents glu-
tathione (GSH) and N-acetylcysteine (NAC), inhibited edelfosine-induced cell death in L.
panamensis promastigotes (Fig 5C). Likewise, cyclosporin A, GSH and NAC inhibited edelfo-
sine-induced apoptosis in human T-cell leukemia Jurkat cells (Fig 5D). Taken together, our
data suggest a critical role of mitochondria in the antileishmanial and antitumor activities of
edelfosine, and that both ROS generation and ΔΨm disruption are involved in edelfosine-
induced cell death in Leishmania parasites and human cancer cells.
Effects of respiration inhibitors and uncouplers on edelfosine-induced
ROS generation in Leishmania and tumor cells
We next examined whether the mitochondrial respiration chain was involved in edelfosine-
induced ROS production, by using the following mitochondrial respiration inhibitors: rote-
none, complex I inhibitor; malonate, complex II inhibitor; antimycin A, complex III inhibitor;
azide, complex IV inhibitor; oligomycin, mitochondrial FOF1-ATP synthase inhibitor; and car-
bonyl cyanide m-chlorophenyl hydrazone (CCCP), one of the most frequently used uncou-
plers of oxidative phosphorylation [51]. Incubation of cells with CCCP, which disrupts the
proton gradient by carrying protons across the mitochondrial membrane and causes mito-
chondrial depolarization, prompted the generation of ROS in L. panamensis and Jurkat cells,
and increased edelfosine-induced ROS generation (Fig 5E and 5F). Incubation of L. panamen-
sis and Jurkat cells for 9 h with rotenone, malonate, antimycin A or azide, affecting the electron
transport at specific sites, neither promoted ROS generation nor affected edelfosine-mediated
ROS production significantly (Fig 5E and 5F). In contrast, oligomycin, a specific inhibitor of
the membranous proton channel (FO) of mitochondrial FOF1-ATP synthase [52], reduced
ROS production levels induced by edelfosine in L. panamensis and Jurkat cells (Fig 5E and 5F).
Lower concentrations of oligomycin in L. panamensis (1 μM) as compared to Jurkat cells (10
panamensis promastigotes and (C) HeLa cancer cells were incubated with 10 μM PTE-ET (blue fluorescence) for 1 h, 100 nM MitoTracker (red fluorescence)
for 20 min to localize mitochondria, and then analyzed by fluorescence microscopy. Areas of colocalization between mitochondria and PTE-ET in merge
panels are purple. The corresponding differential interference contrast (DIC) images are also shown. Images are representative of three independent
experiments. Bar, 20 μm.
https://doi.org/10.1371/journal.pntd.0005805.g004
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Fig 5. Involvement of mitochondria and ROS generation in edelfosine-induced cell death in
Leishmania parasites and cancer cells. (A) L. panamensis promastigotes were untreated (Control) or
treated with 10 μM edelfosine at the indicated times, and cells with disrupted ΔΨm (DiOC6(3)low) and ROS
production (HE!Eth) were measured by flow cytometry. The numbers in each quadrant refer to the
percentages of cells in each population. (B) L. panamensis promastigotes untreated (Control) and treated
with edelfosine (EDLF) for 3 h were incubated with 2 μM HE and 10 μg/ml Hoechst 33342, and then analyzed
by fluorescence microscopy. (C) L. panamensis promastigotes and (D) Jurkat cells were preincubated with
10 μg/ml CsA for 1 h, or with 10 mM NAC or 10 mM GSH for 2 h, and then incubated in the absence or
presence of 10 μM edelfosine for 9 h. After treatment, the percentage of hypodiploid cells was analyzed by
flow cytometry. Untreated control cells were run in parallel. (E) L. panamensis promastigotes and (F) Jurkat
cells were preincubated with 10 μM rotenone, 5 mM malonate, 10 μM antimycin A, 1.5 mM azide, 50 μM
CCCP or with 1 and 10 μM oligomycin (L. panamensis and Jurkat cells, respectively) for 1 h, and then
incubated in the absence or presence of 10 μM edelfosine for 9 h. After treatment, cells producing ROS were
quantified by flow cytometry. Untreated control cells were run in parallel. Data shown are means ± SD or
representative of three independent experiments performed. Asterisks denote that the differences between
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μM) were used, because Leishmania parasites were very sensitive to higher concentrations of
oligomycin, resulting in cytotoxicity. Thus, our data suggest that FOF1-ATP synthase plays a
role in edelfosine-mediated ROS production in both Leishmania and tumor cells, a process
that eventually leads to cell death.
Bcl-XL inhibits cell death in Leishmania and tumor cells
In order to generalize and further support the role of mitochondria in edelfosine-induced cell
death in Leishmania parasites and tumor cells, L. infantum and HeLa cells stably transfected
with the expression vectors pX63-Neo (Leishmania) and pSFFV-Neo (HeLa), containing the
human bcl-xL open reading frame (pX63-bcl-xL and pSFFV-bcl-xL, respectively), were used. L.
infantum and HeLa cells transfected with control empty pX63-Neo and pSFFV-Neo plasmids,
respectively, were used as controls and behaved similarly to wild-type nontransfected Leish-
mania promastigotes and tumor cells, regarding edelfosine-induced cell death (Table 1). We
found that Bcl-XL ectopic expression in L. infantum promastigotes and HeLa tumor cells
inhibited the percentage of hypodiploid cells following edelfosine treatment (Table 1), further
supporting the critical role of mitochondria in the induction of apoptosis-like cell death in
Leishmania and tumor cells treated with edelfosine. The concentration of edelfosine was
increased to 40 μM in the case of L. infantum promastigotes as they were rather resistant to
APL treatment [26]. Taken together, these assays support a crucial role of mitochondria in
edelfosine-induced cell death in both Leishmania spp. parasites and tumor cells. Thus, our
results with two different species of Leishmania, causing distinct forms of disease, namely L.
panamensis (cutaneous and mucocutaneous leishmaniasis) and L. infantum (visceral leish-
maniasis), converge on the critical role of mitochondria in the killing activity of edelfosine on
Leishmania parasites.
the indicated groups (C and D) and with control cells (E and F) are statistically significant. (*) P<0.05. (**)
P<0.01.
https://doi.org/10.1371/journal.pntd.0005805.g005
Table 1. Inhibition of apoptosis-like cell death by ectopic expression of Bcl-XL in L. infantum promas-
tigotes and HeLa tumor cells.
% Hypodiploid cells
Cells Control Edelfosine
L. infantum (wild type) 1.9 ± 0.5 25.3 ± 2.1
L. infantum-pX63 2.1 ± 0.7 27.8 ± 2.5
L. infantum-Bcl-XL 2.0 ± 0.5 11.7 ± 2.0*
HeLa (wild type) 2.8 ± 0.7 35.1 ± 2.7
HeLa-pSFFV 3.3 ± 0.9 38.5 ± 3.2
HeLa-Bcl-XL 3.1 ± 0.8 4.1 ± 1.0**
Parasites, wild type and transfected with the empty expression vector pX63 (L. infantum-pX63) or pX63-bcl-
xL (L. infantum-Bcl-XL), and HeLa cancer cells, wild type and transfected with the empty expression vector
pSFFV (HeLa-pSFFV) or pSFFV-bcl-xL (HeLa-Bcl-XL), were incubated with 40 μM (L. infantum) or 10 μM
(HeLa) edelfosine for 24 h, and then the percentage of hypodiploid cells (proportion of cells in the sub-G1 cell
cycle region) was determined by flow cytometry. Untreated control cells were run in parallel. Data shown are
means ± SD of three independent experiments.
Asterisks indicate values that are significantly different from drug-treated cells transfected with the empty
vectors pX63 and pSFFV, respectively, at P<0.05 (*) and P<0.01 (**).
https://doi.org/10.1371/journal.pntd.0005805.t001
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Lipid raft involvement in the uptake and cytotoxic action of edelfosine in
Leishmania promastigotes and tumor cells
Because membrane rafts are a major target in the antitumor action of edelfosine [17–19, 36,
39], we analyzed, in a comparative way, the putative role of lipid rafts in the antileishmanial
and anticancer activities of edelfosine. First, we found that raft disruption by preincubation of
L. panamensis promastigotes with the cholesterol-depleting agent MCD [53], led to a partial,
but statistically significant, inhibition of both edelfosine-induced cell death (Fig 6A) and edel-
fosine uptake (Fig 6B), suggesting a role for lipid rafts in Leishmania cell death. In addition,
cholesterol depletion by MCD strongly inhibited edelfosine-induced cell death and drug
uptake in the human T-cell leukemia Jurkat cells (Fig 6A and 6B). It is interesting to note that
edelfosine uptake, assessed by the incorporation of [3H]edelfosine, was higher in Leishmania
promastigotes than in tumor cells.
Mitochondrial FOF1-ATP synthase is translocated into L. panamensis
and leukemic Jurkat cell lipid rafts and modulates parasite and cancer
cell killing upon edelfosine treatment
The anticancer activity of edelfosine has been shown to depend on the redistribution of lipid
raft protein composition [17–19, 36, 38, 39, 54]. Because the above data indicated a remarkable
parallelism between the mechanisms of action of edelfosine against Leishmania parasites and
leukemic cells, we next isolated lipid rafts from untreated and edelfosine-treated L. panamensis
promastigotes by fractionation of low-density detergent-insoluble membranes using discon-
tinuous sucrose density gradient centrifugation. The position of lipid rafts in the sucrose gradi-
ents was determined by the presence of ganglioside GM1, detected using the GM1-specific
ligand CTx B subunit (Fig 7A), which binds ganglioside GM1 [55], mainly found in rafts [56].
Following a proteomic study of the lipid raft fractions in L. panamensis promastigotes, we
found a dramatic translocation to lipid rafts of mitochondrial FOF1-ATP synthase β subunit
following drug incubation in L. panamensis promastigotes (Fig 7B and 7C). In addition, we
found that oligomycin inhibited edelfosine-induced ΔΨm disruption and cell death in Leish-
mania (Fig 7D). These data suggest the involvement of FOF1-ATP synthase and its transloca-
tion to lipid rafts in the anti-Leishmania activity of edelfosine.
We also isolated lipid rafts from untreated and edelfosine-treated human T-cell leukemia
Jurkat cells through sucrose gradient centrifugation, and the fractions enriched in lipid rafts
were identified using the GM1-specific ligand CTx B subunit (Fig 8A). Similarly to L. pana-
mensis parasites, a proteomic study of the lipid raft fractions from untreated and drug-treated
cancer cells showed a major translocation of mitochondrial FOF1-ATP synthase β subunit to
lipid rafts upon drug incubation in Jurkat cells (Fig 8B and 8C). Furthermore, oligomycin
inhibited edelfosine-induced ΔΨm loss and cell death in Jurkat cells (Fig 8D).
Genetic abolishment of FOF1-ATP synthase activity blocks edelfosine
cytotoxicity in Saccharomyces cerevisiae yeast
Because the above data suggested that FOF1-ATP synthase could play a major role in the cyto-
toxic activity of edelfosine against Leishmania promastigotes and cancer cells, we next sought
to obtain genetic evidence for the role of this enzyme in edelfosine cytotoxicity by using yeast
as a eukaryotic model organism. We used Saccharomyces cerevisiae yeast atp7Δ mutant, with a
deletion in the gene encoding for subunit d of the stator stalk of mitochondrial FOF1-ATP
synthase, which is conserved in mammalian cells [57]. Since yeast is a facultative anaerobe and
can survive with severely crippled mitochondrial function, we employed S. cerevisiae, which
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has been previously shown to be sensitive to edelfosine [58], as a good model for genetic abla-
tion assays. We chose the yeast atp7Δ mutant because ATP7 is essential for FOF1-ATP synthase
function, but is not essential for growth in yeast. ATP7 deletion leads to a “petite” phenotype
that is slow-growing and unable to survive on nonfermentable carbon sources [57].
We found that edelfosine inhibited wild-type yeast growth at 30 and 60 μM (Fig 9A), but
atp7Δ mutant strain was resistant at these drug concentrations (Fig 9B). This edelfosine-resis-
tant phenotype was reverted by transformation of the atp7Δ mutant with a centromeric
Fig 6. Involvement of lipid rafts in both antileishmanial and anticancer activities and in edelfosine
uptake in Leishmania promastigotes and cancer cells. (A) L. panamensis promastigotes and T-cell
leukemia Jurkat cells were untreated (Control) or pretreated with MCD, and then incubated in the absence or
presence of 10 μM edelfosine for 24 h. Percentage of hypodiploid cells were measured by flow cytometry. (B)
L. panamensis promastigotes and T-cell leukemia Jurkat cells were untreated (Control) or pretreated with
MCD and then incubated with 10 μM [3H]edelfosine for 1 h. Drug uptake was determined as shown in the
Materials and Methods section. Data shown are means ± SD of three independent experiments performed.
Asterisks denote that the differences between the indicated groups are statistically significant. (**) P<0.01.
(***) P<0.001.
https://doi.org/10.1371/journal.pntd.0005805.g006
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plasmid containing the atp7 wild-type gene (Fig 9C). Taken together, these results strongly
support the involvement of FOF1-ATPase in the killing activity of edelfosine.
Discussion
Leishmaniasis therapy is currently far from satisfactory and search for novel druggable targets
and new therapeutic approaches is urgently needed. APLs, originally developed as anticancer
agents, have proved to show antileishmanial activity, but their mechanisms of action remain to
be fully elucidated. Our data reported here indicate that the APL edelfosine is a promising
drug against Leishmania spp. parasites and tumor cells, and unveil common underlying pro-
cesses in the killing activity of this APL on both Leishmania and cancer cells. Edelfosine killed
both Leishmania promastigotes and amastigotes by an apoptosis-like process involving DNA
Fig 7. FOF1-ATPase recruitment into rafts in the antileishmanial activity of edelfosine and oligomycin inhibitory effect on cytotoxicity. (A) L.
panamensis promastigotes untreated (Control) and treated with 10 μM edelfosine for 9 h were lysed in 1% Triton X-100 and subjected to discontinuous
sucrose density gradient centrifugation. Individual fractions were electrophoresed, and location of GM1 was determined. (B) Proteins from lipid rafts of
untreated control and edelfosine-treated L. panamensis promastigotes were subjected to two-dimensional gel electrophoresis followed by MALDI-TOF
analysis. Mitochondrial FOF1-ATP synthase β subunit is indicated by an arrow. (C) Mass spectrum of the tryptic peptides of the FOF1-ATP synthase β subunit
spot. Mass values (m/z) and putative amino acid position assignments are indicated above peaks. (Inset) Peptide coverage map of Leishmania FOF1-ATP
synthase β subunit; the peptides used for identification are highlighted in bold characters and underlined. (D) L. panamensis were untreated (Control) or
preincubated with 1 μM oligomycin for 1 h and then incubated in the absence or presence of 10 μM edelfosine for 9 h, and ΔΨm disruption (Low ΔΨm) and
DNA breakdown (hypodiploids) were evaluated. Data shown are means ± SD or representative of three independent experiments. (*) P<0.05. (**) P<0.01.
https://doi.org/10.1371/journal.pntd.0005805.g007
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breakdown, and edelfosine oral treatment exerted a potent in vivo antileishmanial activity. We
found here that edelfosine killed intracellular Leishmania amastigotes within macrophages, but
spared the host cells. Results reported here point out a number of remarkable actions of edelfo-
sine on macrophages, namely: a) normal BMM take up edelfosine, but unlike cancer cells, they
are spared; b) edelfosine accumulates in the Leishmania amastigotes inside macrophages; c)
edelfosine treatment, in vitro and in vivo, reduces the pro-inflammatory capacity of macro-
phages. These results suggest that edelfosine kills Leishmania parasites by acting directly on the
parasite. Edelfosine and other APLs have been shown to act rather selectively on a wide range of
malignant cells, mainly due to their predominant uptake by tumor cells [15, 17–19, 43, 59]. The
Fig 8. FOF1-ATPase recruitment in lipid rafts of Jurkat cancer cells after edelfosine incubation and oligomycin inhibitory effect on cytotoxicity. (A)
Jurkat cells untreated (Control) and treated with 10 μM edelfosine for 9 h were lysed in 1% Triton X-100 and subjected to discontinuous sucrose density
gradient centrifugation. Individual fractions were subjected to SDS-PAGE, and location of GM1 was determined using CTx B subunit conjugated with
horseradish peroxidase. (B) Proteins from lipid rafts of untreated control and edelfosine-treated Jurkat cells were subjected to two-dimensional gel
electrophoresis followed by MALDI-TOF analysis. Mitochondrial FOF1-ATP synthase β subunit is indicated by an arrow. (C) Mass spectrum of the tryptic
peptides of the FOF1-ATP synthase β subunit spot. Mass value (m/z) and putative amino acid position assignments are indicated above peaks. (Inset) Peptide
coverage map of human FOF1-ATP synthase β subunit; the peptides used for identification are highlighted in bold characters and underlined. (D) Jurkat cells
were untreated (Control) or preincubated with 10 μM oligomycin for 1 h and then incubated in the absence or presence of 10 μM edelfosine for 9 h, and ΔΨm
disruption (Low ΔΨm) and DNA breakdown (hypodiploids) were evaluated. Data shown are means ± SD or representative of three independent experiments.
Asterisks denote that the differences between the indicated groups are statistically significant. (**) P<0.01.
https://doi.org/10.1371/journal.pntd.0005805.g008
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Fig 9. Edelfosine resistance of atp7Δmutant in Saccharomyces cerevisiae yeast. Growth curves of wild-
type (BY4741) (A), ATP7 knock-out mutant (atp7Δ) (B) and the mutant strain harboring the corresponding
cognate gene (atp7Δ+pRS416-ATP7) (C) in SDC medium containing different concentrations of edelfosine.
The cultures were carried out in duplicate and in at least three independent experiments. Data shown are mean
values of three independent experiments. SD values were less than 10% of the mean values.
https://doi.org/10.1371/journal.pntd.0005805.g009
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ability of macrophages to take up edelfosine constitutes the first evidence for the incorporation
of edelfosine in a normal resting cell type at similar amounts as in cancer cells. This is of major
importance in leishmaniasis because macrophages are the main host cells in Leishmania infec-
tion. We have previously found that the fluorescent edelfosine analog PTE-ET accumulated
into naïve macrophages, especially around the nucleus, but once naïve macrophages were
infected with Leishmania spp., an intense fluorescent signal was detected in the intracellular
parasites [26]. These data, together with the findings reported here, indicate that edelfosine is
taken up by naïve macrophages in significant amounts, and therefore it might affect some mac-
rophage functions, such as the ones herein described, namely, a decrease in the generation of
superoxide anion and nitric oxide, as well as in the production of IL-12+IL-18-induced IFN-γ.
Interestingly, when Leishmania parasites enter the macrophage, a substantial amount of drug is
translocated to the sites where the parasites are located and then the drug is incorporated into
the protozoa [26]. Thus, edelfosine could affect both macrophage functions and Leishmania sur-
vival. The finding that edelfosine diminishes the capacity of macrophages to mount an inflam-
matory response might be relevant, as severe inflammation at the site of infection leads to tissue
destruction in leishmaniasis [60]. In this regard, edelfosine has also been reported to display a
potent anti-inflammatory action through L-selectin shedding in human neutrophils, thus pre-
venting neutrophil extravasation [31], and recent in vivo evidence further supports the anti-
inflammatory and immunomodulatory effect of edelfosine [61–63]. Furthermore, edelfosine
promotes apoptosis in mitogen-activated T lymphocytes [64]. On these grounds, edelfosine can
affect in different ways the major leukocyte types involved in inflammation, namely neutrophils,
macrophages and lymphocytes, thus leading eventually to decreased inflammatory responses.
We have also found here that edelfosine accumulates in mitochondria in both Leishmania
parasites and tumor cells, leading to ΔΨm loss and an apoptosis-like cell death. These results
agree with recent reports showing a major location of different fluorescent edelfosine analogs
in the mitochondria of cancer cells [37, 65]. Our data indicate that edelfosine induces firstly
DNA fragmentation in the Leishmania kinetoplast-mitochondrion followed by nuclear DNA
breakdown, while cell death in Leishmania parasites and tumor cells can be inhibited by pro-
tecting mitochondria through ectopic Bcl-XL expression. These results indicate a critical role
of mitochondria in the edelfosine-induced cell killing mechanism in Leishmania parasites and
tumor cells. Interestingly, the data reported here suggest that FOF1-ATP synthase plays a prin-
cipal role in the edelfosine-induced killing activity in both Leishmania parasites and cancer
cells. The involvement of the FOF1-ATP synthase in edelfosine cytotoxicity was further
assessed through gene deletion experiments conducted in yeast, by showing that the lack of
ATP7, which results in a defective FOF1-ATP synthase, inhibited edelfosine toxicity. Drug sen-
sitivity was restored when atp7Δ mutant yeast were transformed with the cognate wild-type
gene. Thus, the results shown here strongly indicate by genetic and biochemical approaches
that FOF1-ATP synthase is involved in the killing activity of edelfosine in both Leishmania par-
asites and human tumor cells.
The major role of mitochondria in edelfosine-induced Leishmania killing was further
assessed by the generation of ROS in the parasite mitochondrion and the involvement of ROS
in edelfosine-induced Leishmania promastigote cell death. Interestingly, edelfosine-induced
ROS generation in Leishmania promastigotes was inhibited by oligomycin, an inhibitor of the
FO subunit of the mitochondrial FOF1-ATP synthase. Taken together, our data suggest a role
for mitochondria and ROS generation in the execution of edelfosine-mediated apoptosis, and
oligomycin is able to prevent edelfosine-induced ΔΨm collapse and DNA degradation in both
Leishmania parasites and cancer cells. These data highlight a major role of the FO component
of the FOF1-ATP synthase in the edelfosine-induced ΔΨm dissipation, ROS generation and cell
death. In this regard, the involvement of FOF1-ATP synthase in the apoptotic response induced
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in glioblastoma cells by erucylphosphomocholine (ErPC3, Erufosine), another APL member,
has been suggested [66]. Furthermore, oligomycin has also been reported to suppress TNF-
induced apoptosis in human epithelioid carcinoma HeLa cells [67].
The mechanism by which FOF1-ATPase contributes to edelfosine-induced cell death remains
to be established. FOF1-ATPase resides in the inner membrane of mitochondria and can pump
protons in forward and reverse directions, either pumping protons into the mitochondrial
matrix, flowing down their concentration gradient and leading to ATP generation, or pumping
protons out of the mitochondrial matrix while hydrolyzing ATP. Because edelfosine affects
membrane lipid organization, making membranes more fluid [68, 69], it might be suggested
that edelfosine makes the outer membrane more porous, thus favoring the leakage of H+ ions
from the outer-inner intermembrane space into the cytosol, which leads to the dissipation of
the proton gradient. As a consequence, the FOF1-ATP synthase could run in reverse, that is,
hydrolyzing ATP and alkalinizing the matrix by proton extrusion. Because matrix alkalinization
has been shown to cause opening of the mitochondria permeability transition pore [70], the
FOF1-ATP synthase could facilitate cell death by this mechanism. This explanation has been pre-
viously proposed for the effect of oligomycin in inhibiting Bax-induced apoptosis in yeast and
mammalian cells [71]. In this regard, we have found that edelfosine treatment led to a reduction
in the ATP content of L. panamensis promastigotes (Fig 10).
Furthermore, edelfosine has been reported to act through lipid rafts in human leukemic can-
cer cells [17–19, 22, 23, 36, 39], and recent evidence suggests a raft-mediated connection
between the cell membrane and mitochondria in the action of edelfosine [20, 37, 38]. Here, we
have found the involvement of lipid rafts in the antileishmanial activity of edelfosine, and edel-
fosine treatment led to a dramatic recruitment of mitochondrial FOF1-ATP synthase into rafts
in both Leishmania promastigotes and cancer cells. These findings are in line with the identifi-
cation of lipid rafts in Leishmania parasites [24], and with the impairment of miltefosine action
against L. donovani by membrane sterol depletion [72]. The results reported here suggest a
redistribution of the FOF1-ATP synthase within the mitochondria or to additional raft domains
in other cellular membranes following edelfosine treatment, thus altering the normal function
of the enzyme and affecting cell viability. It could also be envisaged that the action of edelfosine
Fig 10. Intracellular ATP measurements. L. panamensis promastigotes were treated with 10 μM edelfosine
or 50 μM CCCP for different incubation times and processed for ATP intracellular content. Results are
expressed as percentage of the amount of ATP found in untreated control cells. Data shown are means ± SD
of three independent experiments.
https://doi.org/10.1371/journal.pntd.0005805.g010
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on lipid rafts and mitochondria might underlie the inhibition of superoxide anion production
in edelfosine-treated macrophages, generated by the NADPH-oxidase located at the macro-
phage cell membrane [73], and the enhancement of mitochondria-dependent ROS generation
in drug-sensitive cells.
The results reported here highlight a major role for mitochondria and lipid rafts in the
mechanism of action of edelfosine as both antileishmanial and anticancer drug. Nevertheless,
cancer cells seem to be more dependable on lipid rafts than parasites, as shown by the relatively
higher inhibition observed in drug uptake and drug-induced cell death when rafts were dis-
rupted by sterol depletion (Fig 6). This putative mechanism of action involving mitochondria,
and briefly depicted in Fig 11, seems to be common to both Leishmania parasites and tumor
cells. The fact that protecting mitochondria by Bcl-XL ectopic expression leads to an inhibition
in drug-induced cell death, further supports the major role of mitochondria and mitochon-
drial-mediated pathways in the killing activity of edelfosine in both Leishmania parasites and
human cancer cells. Previous data on human cancer cells have demonstrated the involvement
of mitochondria in the pro-apoptotic activity of edelfosine as an antitumor drug [16, 18, 20,
37, 38, 46, 74], and the results reported here extrapolate this notion to its leishmanicidal activ-
ity. In addition, the present results pinpoint the major role of FOF1-ATPase in the killing activ-
ity of edelfosine against Leishmania parasites and tumor cells. We have previously found a link
between lipid rafts and mitochondria in the mechanism of action of edelfosine [37, 38], sug-
gesting an edelfosine-mediated redistribution of lipid rafts from the plasma membrane to
mitochondria [37, 38]. The results reported here indicate that FOF1-ATPase is either translo-
cated to cell surface lipid rafts or to raft domains present in mitochondria. A number of reports
have shown the presence of raft-localized FOF1-ATP synthase at the cell surface of several cell
types, having been proposed to act as a receptor for different ligands, a proton channel, or a
modulator of extracellular ATP levels, involved in numerous biological processes through still
unclear mechanisms [75–81]. Our results cannot discern between a cell surface and a mito-
chondrial localization for the raft-associated FOF1-ATP synthase following edelfosine treat-
ment reported here. Thus, a putative translocation of the mitochondrial FOF1-ATP synthase to
the cell surface cannot be ruled out at the moment, and additional experimental approaches
should be applied to elucidate the prevailing localization of raft-located FOF1-ATP synthase.
However, our present data indicating an accumulation of the ether lipid in the mitochondria
of both Leishmania parasites and cancer cells, lead us to suggest that a plausible mechanism
could involve the translocation of edelfosine from the plasma membrane to the mitochondria
where it would ultimately exert its cytotoxic activity promoting the accumulation of FOF1-ATP
synthase into mitochondrial rafts, and leading to the dissipation of the mitochondrial mem-
brane potential, ROS generation, and eventually cell demise (Fig 11). The fact that kineto-
plast-mitochondrion was the first organelle where ROS metabolites were generated and
DNA was broken down, preceding nuclear DNA fragmentation, points out the critical role
of mitochondria as a major target in the search for effective drugs to treat leishmaniasis. It is
tempting to suggest that a link between lipid rafts and mitochondria could lead to interest-
ing hints to unveil a novel framework in both Leishmania and cancer therapy. The present
data also indicate that our insight on how edelfosine works as an antitumor drug can be of
great aid to and give valuable information to uncover the mechanism of action of its leish-
manicidal activity, which could be hypothetically extrapolated to other antileishmanial
drugs, and might be of inspiration to further identify potential common therapeutic targets
in cancer and leishmaniasis.
Taken together, our data indicate that the edelfosine antileishmanial and antitumor mecha-
nisms of action share similar molecular processes, involving mitochondria, lipid rafts and
FOF1-ATPase. This study provides a molecular explanation on how the antitumor drug
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edelfosine acts as an antileishmanial agent, and highlights that mitochondria, lipid rafts and
FOF1-ATPase act as major players in cell death modulation, opening new avenues for thera-
peutic intervention in leishmaniasis and cancer. Our results show that the ether phospholipid
edelfosine can be a promising orally administered therapeutic agent and a lead compound in
the search for novel and much-needed antileishmanial agents, and identify lipid rafts, mito-
chondria and FOF1-ATPase as appealing new antileishmanial targets. Furthermore, the results
shown here indicate that edelfosine is very effective in killing different species of Leishmania
parasites, as well as in distinct developmental stages, such as promastigotes and amastigotes.
Interestingly, recent data have shown an increasing rate of relapse against miltefosine and a
decline in its efficacy [82–85], which could correspond to the readiness in acquiring experi-
mental drug resistance to miltefosine in vitro [86–88]. We have previously shown that edelfo-
sine is less prone to lead to drug resistance development than miltefosine, and displays a
higher antileishmanial activity than miltefosine against a wide variety of Leishmania spp. [26].
Fig 11. Schematic model of mitochondria involvement in the killing activity of edelfosine against Leishmania parasites and tumor cells. This is a
schematic diagram to portray one currently plausible mechanism of how edelfosine induces cell death in Leishmania parasites and tumor cells through its
main mitochondrial localization in both biological systems. Protection of mitochondria by Bcl-XL ectopic expression restrains cell death. See text for details.
https://doi.org/10.1371/journal.pntd.0005805.g011
Mitochondria and raft-located FOF1-ATPase in
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005805 August 22, 2017 25 / 31
Thus the potent leishmanicidal activity of edelfosine, together with its low toxicity profile [31],
warrants further clinical evaluation for this ether lipid as a possible therapeutic agent against
different forms of leishmaniasis.
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